The prognoses of xenograft tumor models were recorded, and the results showed that although the PARP inhibitors (olaparib and AG14361) did not significantly prolong the survival times of the animals with SKOV3-derived xenograft tumors, oxamate compensated for this shortcoming (Figure 4E, 4F). The gene discussed is PARP1; the disease is neoplasm.